PROCEPT BioRobotics (PRCT) shares have been under pressure recently, sliding 15% over the past month and dropping 41% in the past 3 months. Investors may be weighing the company’s longer-term growth prospects against near-term challenges.

See our latest analysis for PROCEPT BioRobotics.

PROCEPT BioRobotics's share price momentum has faded sharply in 2024, with a year-to-date share price return of -58.4% and a 12-month total shareholder return down 53.2%. The drastic decline reflects shifting sentiment around near-term risks. However, the company’s long-term outlook keeps some investors interested.

If you’re keeping an eye on healthcare innovators tackling big challenges, this could be the perfect moment to explore See the full list for free.

With shares trading well below analyst price targets while significant risks cloud the near term, investors have to ask themselves whether this is a rare bargain in an innovative sector or if the market is already discounting future growth.

With the most closely watched narrative in the market placing fair value at $65.60, PROCEPT BioRobotics's last close at $34.61 paints a striking contrast. The numbers point to ongoing caution, yet some believe the company is poised for a pivotal turn.

Robust procedure growth is underpinned by increasing surgeon adoption and a meaningful shift toward minimally invasive therapies. This aligns with broader healthcare trends and supports durable net revenue and margin expansion as clinical outcomes continue to validate Aquablation as standard of care.

Read the complete narrative.

What is the real story behind this aggressive fair value? Analysts are betting on step-change growth, stronger margins, and a transformation that could surprise even the optimists. The crucial details fueling this bold re-rating are revealed deep inside the projections. Curious what turns this into a potential healthcare standout? Don’t miss the full breakdown.

Result: Fair Value of $65.60 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent operating losses and heavy reliance on its core platform could quickly undermine confidence if growth or adoption stumbles.

Find out about the key risks to this PROCEPT BioRobotics narrative.

Looking through the lens of market pricing, PROCEPT BioRobotics trades at a price-to-sales ratio of 7x. This is far higher than the US Medical Equipment sector average of 2.8x, the peer average of 4.3x, and even the fair ratio of 4.4x that the market could gravitate toward. Such a premium suggests investors are pricing in a lot of future growth. However, it also leaves little room for disappointment and raises the stakes if results miss expectations. Is this high bar justified or a warning signal?

See what the numbers say about this price — find out in our valuation breakdown.

Don’t see your own view reflected here, or want to dig deeper into the numbers? You can analyze the data yourself and shape your own perspective in just a few minutes with Do it your way.

A great starting point for your PROCEPT BioRobotics research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.

Smart investors never settle for just one opportunity. Uncover what could be your next big winner by checking out these handpicked stock ideas before everyone else does.

Lock in high yields by scanning 3%;elm:context_link;itc:0;sec:content-canvas\\" class=\\"link \\">these 19 dividend stocks with yields > 3%. These consistently outperform with payouts above 3 percent year after year.

Unleash the potential of artificial intelligence by targeting these 25 AI penny stocks. These are breaking new ground in automation and next-gen technology.

Catch tomorrow's game changers early by targeting these 3579 penny stocks with strong financials with the strongest fundamentals among rapidly emerging companies.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include PRCT.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com